Panitumumab
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Administer intravenously only through an in-line low-protein-binding 0.2-micron filter over 60 minutes (doses <=1000 mg) or 90 minutes (doses >1000 mg) every 14 days (6 mg/kg). Do NOT administer as an IV push or bolus. Premedicate with antihistamines and corticosteroids.
⚠️ Side Effects
Common: Papulopustular acneiform skin rash, paronychia, pruritus, erythema, diarrhea, hypomagnesemia, fatigue, nausea. Rare/Severe: Fatal infusion reactions, pulmonary fibrosis / interstitial lung disease, ocular keratitis, and severe hypomagnesemia / hypokalemia.
🛡️ Safety Warnings
Black Box Warning: Dermatologic and soft tissue toxicity (severe acneiform rash occurs in >90% of patients; withhold or reduce dose for grade 3+ toxicity); apply prophylactic moisturizers and sunscreens. Black Box Warning: Ineffective in patients with mutated RAS (KRAS/NRAS) colorectal tumors; genetic testing for wild-type RAS is mandatory prior to therapy. Monitor serum magnesium and calcium weekly.
Jan Aushadhi Products containing Panitumumab
Found 2 generic formulation(s) containing this active ingredient.
Panitumumab 100mg Infusion
Panitumumab Infusion (100mg, 400mg) is a recombinant, fully human IgG2 monoclonal antibody on the WHO Model List of Essential Medicines that binds specifically to the human Epidermal Growth Factor Receptor (EGFR / HER1). It competitively prevents binding of endogenous EGF and TGF-alpha, halting EGFR dimerization, receptor autophosphorylation, and downstream pro-proliferative intracellular cascades. Indicated for wild-type KRAS and NRAS (exon 2, 3, and 4) metastatic colorectal carcinoma (mCRC), as first-line therapy with FOLFOX, or as monotherapy following progression on oxaliplatin, irinotecan, and fluoropyrimidines.
Panitumumab 400mg Infusion
Panitumumab Infusion (100mg, 400mg) is a recombinant, fully human IgG2 monoclonal antibody on the WHO Model List of Essential Medicines that binds specifically to the human Epidermal Growth Factor Receptor (EGFR / HER1). It competitively prevents binding of endogenous EGF and TGF-alpha, halting EGFR dimerization, receptor autophosphorylation, and downstream pro-proliferative intracellular cascades. Indicated for wild-type KRAS and NRAS (exon 2, 3, and 4) metastatic colorectal carcinoma (mCRC), as first-line therapy with FOLFOX, or as monotherapy following progression on oxaliplatin, irinotecan, and fluoropyrimidines.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Panitumumab.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Panitumumab 100mg Infusion | 5ml Vial | Under Process | N/A | N/A | N/A |
| Panitumumab 400mg Infusion | 20ml Vial | Under Process | N/A | N/A | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Panitumumab generics.